[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evogene Ltd Ord (EVGN)

Evogene Ltd Ord (EVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,730
  • Shares Outstanding, K 8,718
  • Annual Sales, $ 3,850 K
  • Annual Income, $ -8,490 K
  • EBIT $ -13 M
  • EBITDA $ -11 M
  • 60-Month Beta 1.40
  • Price/Sales 1.23
  • Price/Cash Flow N/A
  • Price/Book 0.59
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.14
  • Most Recent Earnings $-0.60 on 05/20/26
  • Next Earnings Date 08/18/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3700 +46.62%
on 06/26/26
0.6797 -20.19%
on 07/17/26
+0.1033 (+23.52%)
since 06/24/26
3-Month
0.3700 +46.62%
on 06/26/26
0.8500 -36.18%
on 05/07/26
-0.2455 (-31.15%)
since 04/24/26
52-Week
0.3700 +46.62%
on 06/26/26
1.5000 -63.83%
on 10/08/25
-0.8075 (-59.81%)
since 07/24/25

Most Recent Stories

More News
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

Collaboration combines Evogene's AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar...

EVGN : 0.5425 (-0.04%)
AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Agâ„¢ Capabilities

New AI model enables ChemPass AI for Ag™ to identify and prioritize antifungal molecules with a higher probability of biological success  at early discovery stages

EVGN : 0.5425 (-0.04%)
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery

Supporting Israel's Academic Innovation Ecosystem: BCDD to Provide World-Class Experimental Infrastructure, Evogene to Deliver Computational Chemistry and AI Capabilities

EVGN : 0.5425 (-0.04%)
Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AIâ„¢ Toward Autonomous Small Molecule Discovery and Optimization

Integration of agentic computational systems enables the early-stage definition of key clinical and biological success criteria, accelerating discovery timelines, improving scalability, and increasing...

EVGN : 0.5425 (-0.04%)
Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Conference to be held in San Diego, CA, USA – June 22-25, 2026

EVGN : 0.5425 (-0.04%)
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity

EVGN : 0.5425 (-0.04%)
Evogene: Q1 Earnings Snapshot

Evogene: Q1 Earnings Snapshot

EVGN : 0.5425 (-0.04%)
Evogene Reports First Quarter 2026 Financial Results

Conference call and webcast: today, May 20, 2026, 9:00 AM ET

EVGN : 0.5425 (-0.04%)
Evogene to Present at the 24th Schrödinger European User Group Meeting

Conference will be held in Munich, Germany - May 19-21, 2026

EVGN : 0.5425 (-0.04%)
Evogene Schedules First Quarter 2026 Financial Results Release

Zoom conference call scheduled for May 20, 2026, 9:00 AM ET

EVGN : 0.5425 (-0.04%)

Business Summary

Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene...

See More

Key Turning Points

3rd Resistance Point 0.5853
2nd Resistance Point 0.5722
1st Resistance Point 0.5573
Last Price 0.5425
1st Support Level 0.5293
2nd Support Level 0.5162
3rd Support Level 0.5013

See More

52-Week High 1.5000
Fibonacci 61.8% 1.0683
Fibonacci 50% 0.9350
Fibonacci 38.2% 0.8017
Last Price 0.5425
52-Week Low 0.3700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.